Company news
Soleno Therapeutics, Inc. news in 2022
Soleno Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
December 18, 2022
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 8, 2022
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome
October 2, 2022
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 9, 2022
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
July 19, 2022
Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference
July 10, 2022
Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS
June 12, 2022
Soleno Therapeutics Announces Presentations at ENDO 2022
June 6, 2022
Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology
May 18, 2022
Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 16, 2022
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 9, 2022
Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome
May 1, 2022
Soleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering
March 31, 2022
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
March 30, 2022
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
March 28, 2022
Soleno Therapeutics Announces Proposed Underwritten Public Offering
March 27, 2022
Soleno Therapeutics to Participate in the BIO CEO & Investor Conference
February 7, 2022
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
January 23, 2022
Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event
January 4, 2022